Long-Term Breast Cancer Response to CDK4/6 Inhibition Defined by TP53-Mediated Geroconversion

Using a large, clinically annotated cohort of patients with metastatic hormone receptor-positive breast cancer, scientists identified TP53 loss and MDM2 amplification to be associated with lack of long-term disease control.